ASHPOfficial

Leadership is often associated with a leader taking charge at the frontline. Oftentimes we describe these types of leaders as strong, inspirational, or courageous, however, the biggest impacts don’t always come from the individuals leading the charge. Although they sometimes go unrecognized, “Little L” leaders can be found scattered within the group where they work behind the scenes to empower their teammates and steer them towards success. That is why the concept of “leading from behind” is such a crucial component of ensuring effective team dynamics. If you apply this philosophy to the healthcare landscape, it becomes apparent that the nature of our profession allows pharmacists to act as a prime example of how this leadership style can be effectively utilized. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Acute agitation, particularly in patients with schizophrenia and bipolar disorder, occurs frequently, resulting in multiple visits to the emergency department each year. The management of acute agitation occurs in various departments throughout the hospital and health system. This educational activity will discuss currently recommended patient-centered approaches to care, which includes both nonpharmacologic and pharmacologic treatments. Guideline-recommended approaches that improve the patient experience as well as improve future interactions between patients and healthcare professionals will also be discussed.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode includes an interview with two ID specialty pharmacists and their take on the new Joint Commission requirements that were implemented in 2023. Tune in to learn what they anticipate to be the biggest challenges and opportunities they see from the perspective of a large academic and small community hospital.  

Show notes:

• R3 Report Antibiotic Stewardship: https://www.jointcommission.org/-/media/tjc/documents/standards/r3-reports/r3_antibioticstewardship_july2022_final.pdf

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast provides an engaging interview with a seasoned pharmacy leader to provide listeners with an overview of successful project management. All too often, new leaders and frontline staff involved in projects can become overwhelmed with the steps involved to see a project through. Tina Do, of Yale New Haven Health, will take us through the basics of creating a strong project plan. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this feature from the 2022 Midyear Clinical Meeting, our content matter expert reviews what artificial intelligence is (and isn’t) and identifies  opportunities in health-system pharmacies where artificial intelligence (AI) can be used.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Mpox, formerly known as monkeypox, has been reported in all 50 states. The Navigators discuss how lessons learned from COVID-19 can be applied to manage this latest outbreak and provide insight on current efforts by departments of health and pharmacies to address this newest public health need.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this podcast, Dr. Kenneth Komorny and Nicole Bennett discuss the AJHP Commentary, “Payer site of care mandates with oncology medications: It’s time to demand payer accountability on behalf of patients,” with host and AJHP Editor in Chief Dr. Daniel Cobaugh.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast, produced by ASHP’s Pharmacy Administration and Leadership Residents’ Collaborative (PALRC), delivers an engaging interview with two distinguished pharmacy leaders who have embraced lifelong learning to serve the profession. Jordan Dow and Majid Tanas share their approaches and discuss the importance of lifelong learning. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

With the release of the revised USP <797> guidance, it is important to revisit some of the basics of sterile compounding. The Section of Inpatient Care Practitioner’s SAG on Compounding Practice has developed a three-part series that will cover differing definitions of compounding, beyond use dates (BUDs), and changes from low, medium, and high risk compounding categories. In this third episode of the series, speakers will focus on one of the most significant changes between the currently enforceable version and the upcoming version: the change from low, medium, and high risk to category 1, 2, and 3 compounding and how this impacts BUDs. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

International interest in US-based pharmacy residency training has grown in recent years. With a reduced US pharmacy student pipeline, the desire for health-systems to hire international candidates into residencies is likely to increase. Many Pharmacy administrators and Resident Program Directors in the US are not familiar with visa restrictions for international trainees. This podcast will shed light on training visas and perspectives on this topic.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.